An interprofessional faculty of primary care and specialty clinicians discuss real-world issues in managing patients with complex and challenging dyslipidemia, including elevated lipoprotein a (Lp(a)). Several paired conversations serve as the foundation for discussions related to recent cholesterol guidelines, patient risk stratification, and recommended goals for patients at risk of atherosclerotic cardiovascular disease. Two case vignettes provide the basis for robust discussion among the faculty, which centers around clinical decision-making and the roles, benefits, and limitations of approved and investigational pharmacologic treatment options. The 1.5-hour program format fosters critical thinking and application of key concepts to patient cases, enabling participants to advance their clinical practice.
The conversations are also available as a podcast: You may listen here
Course Credit:
1.5 ACPE Contact Hours
1.5 AMA PRA Category 1 CreditsTM
1.5 ANCC Contact Hours
1.5 CA-BRN Contact Hours
Dates:
Opens: 2023-12-29
Closes: 2024-12-29
Target Audience:
This activity was developed for cardiologists, lipidologists, internal medicine specialists, primary care physicians, nurse practitioners, physician associates/assistants, pharmacists and other clinicians who have a role in the diagnosis, treatment, and monitoring of patients with hyperlipidemia.
This activity is supported by an independent educational grant from Novartis Pharmaceuticals.
Accreditation
The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Annenberg Center for Health Sciences at Eisenhower designates this knowledge-based activity for a maximum of 1.5 hours. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion.
Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1.5 contact hours.
To receive credit for education contact hours outside of the state of California, please check with your state board of registered nursing for reciprocity.
Additional Content Planners
James Backes, PharmD (Medical Writer)No significant relationships to disclose.
Jada Dillner, PA (Peer Reviewer)
No significant relationships to disclose.
Heather Jimenez, MSN, FNP-C (Nurse Reviewer)
No significant relationships to disclose.
Annenberg Center for Health Sciences
Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant financial relationships to disclose.
All of the financial relationships listed for these individuals have been mitigated.
-
John E. Anderson, MD
Internal Medicine and Diabetes
The Frist Clinic
Nashville, Tennessee -
James M. Backes, PharmD
Professor
Associate Dean for Clinical and Medical Center Affairs
Assistant Director Atherosclerosis and LDL-Apheresis Center
School of Pharmacy
Kansas City, Kansas -
Deepak L. Bhatt, MD, MPH
Director, Mount Sinai Heart and the Cardiovascular Institute
Dr. Valentin Fuster Professor of Cardiovascular Medicine
Icahn School of Medicine
Mount Sinai Health System
New York, New York -
Seth S. Martin, MD
Director of the Advanced Lipid Disorders Program and Digital Health Lab
Ciccarone Center for the Prevention of Cardiovascular Disease
Associate Professor of Medicine
Johns Hopkins
Baltimore, Maryland -
Colleen Walsh-Irwin, DNP
Associate Director
Evidence-Based Practice at Department of Veterans Affairs
E. Northport, New York
Presenting Faculty
Learning Objectives
- Understanding of Lp(a) recommendations and management according to recent cholesterol guidelines
- Implement nonstatin therapy among those not achieving lipid treatment targets with or not tolerating statin therapy
- Utilize validated risk assessment tools to classify individual patients
- Recognize lipid targets and thresholds for initiating nonstatin therapy
- Implement strategies to limit common barriers for initiating nonstatin therapies
- Utilize practice cases for understanding guideline recommendations for initiating new therapies
Faculty Disclosures
John E. Anderson, MD
Advisory Board: Abbott Diabetes
Consultant: Bayer, Biolink, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Sanofi
Speakers Bureau: Bayer, Eli Lilly, Novo Nordisk, Sanofi
James M. Backes, PharmD
No relationships to disclose.Deepak L. Bhatt, MD, MPH
Advisory Board: Angiowave, Bayer, Boehringer Ingelheim, CellProthera, Cereno Scientific, Janssen, McKinsey, Merck, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, Stasys
Consultant: GlaxoSmithKline, Hims, SFJ, Youngene
Data Monitoring Committees: Acesion Pharma, Boston Scientific, Contego Medical, Novartis
Honoraria: CSL Behring (AHA lecture), Cowen and Company, Piper Sandler
Research Funding: Abbott, Acesion Pharma, Afimmune, Aker Biomarine, Alnylam, Amarin, Amgen, AstraZeneca, Bayer, Beren, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, CinCor, Cleerly, CSL Behring, Eisai, Ethicon, Faraday Pharmaceuticals, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Javelin, Lexicon, Lilly, Medtronic, Merck, Moderna, MyoKardia, NirvaMed, Novartis, Novo Nordisk, Otsuka, Owkin, Pfizer, PhaseBio, PLx Pharma, Recardio, Regeneron, Reid Hoffman Foundation, Roche, Sanofi, Stasys, Synaptic, The Medicines Company, Youngene, 89Bio
Site Co-Investigator: Abbott, Biotronik, Boston Scientific, CSI, Endotronix, St. Jude Medical (now Abbott), Philips, SpectraWAVE, Svelte, Vascular Solutions; Unfunded Research: FlowCo.
Seth S. Martin, MD
Advisory Board: Amgen, AstraZeneca, BMS, Merck, NewAmsterdam
Consultant: Premier